Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4977 participants
OBSERVATIONAL
2021-05-05
2021-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 STAndard of Care in Sub-Saharan Africa
NCT04885543
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
NCT04832932
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
NCT05244330
Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon
NCT05065632
Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death
NCT04914832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In 2015, WHO's Strategic Advisory Group of Experts on Immunization defined vaccine hesitancy as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services', which can vary in form and intensity based on when and where it occurs and what vaccine is involved. Several prophylactic vaccines against COVID-19 are currently in development. As the world is beginning the roll-out the first approved vaccines, little is known about people's potential acceptance of a COVID-19 vaccine in most of the African countries. A recent study published in Nature provides results on the acceptability of vaccines in 19 of the 35 hardest hit countries worldwide. South Africa was the only African country included in the survey. An additional survey conducted in 15 African countries between August and December 2020, reveals that the majority of Africans would take a safe and effective vaccine. Nevertheless, vaccine hesitancy towards COVID-19 vaccines evolves over-time. In this view, it is crucial to investigate in depth barriers and facilitators influencing vaccine hesitancy/acceptability within African population.
During the last decade several initiatives have emerged that aim at improving vaccine coverage and acceptability across the African continent. A noteworthy example is the Francophone African Civil Society Organizations' Platform for Strengthening Health Systems and Immunization, which has been since 2015 supported by GAVI (Global Alliance for Vaccines and Immunisation). OAFRESS encourages activities among francophone African members, with the primary objective of reinforcing capacities and coordinating strategies among these countries. The last West African Ebola epidemic demonstrated the importance of engaging communities in order to promote vaccine acceptability. The three most hit countries, Guinea, Sierra Leone, and Liberia, worked together and invested in research and campaigns to identify and address barriers and facilitators of vaccine acceptance, which informed both clinical vaccine studies and roll-out strategies.
In order to promote the equitable and prompt roll-out of the COVID-19 vaccine worldwide, as the COVAX initiative strives for, factors influencing vaccine hesitancy in low and middle-income countries need to be investigated more thoroughly. The request for a first roll-out of the vaccines in eligible countries was to be submitted by December 7, 2020. Many of the eligible African countries have placed the order to receive the vaccines, which are already being deployed within these first months of 2021. Country and population preparedness are crucial to making the roll-out a success.
2\. Study Objectives 2.1 Overall objective To investigate COVID-19 vaccine hesitancy among five African countries to inform effective context-specific public health strategies for roll-out of vaccination.
2.2 Primary objectives • To describe and compare levels of COVID-19 vaccine hesitancy among the general population and health care workers in rural and urban settings across African countries
2.3 Secondary objectives
• To explore factors influencing COVID-19 vaccination hesitancy among the general population and health care workers in urban and rural Africa
3\. Methodology 3.1 Study design A cross-sectional survey will be conducted in five African countries. A core study will be implemented in five countries, other countries will enter the study as budget will become available. Study participants will be selected among the general population aged older than 18 and health care workers. Sample sizes have been calculated separately for these two groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
General population
Questionnaire administered to adult population
No interventions assigned to this group
Health care workers
Questionnaire administered to adult health care workers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 18 years of age, be willing and able to provide written informed consent AND
Health professionals
* To be health professionals working in health care institutions at all levels of care for the Ministry of Health (MoH)
* freely consent to participate in the study
In Senegal
* All those already vaccinated or being offered a vaccination for COVID-19 and refused and/or delayed the vaccination
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Recherche en Sciences de la Sante, Burkina Faso
OTHER_GOV
University of Bamako
OTHER
Cheikh Anta Diop University, Senegal
OTHER
University of Sierra Leone
OTHER
Gamal Abdel Nasser University of Conakry
OTHER
Bernhard Nocht Institute for Tropical Medicine
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniela Fusco, PhD
Role: PRINCIPAL_INVESTIGATOR
Bernhard Nocht Institute for Tropical Medicine
Henri Gautier Ouedraogo, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Ouagadougu
Alpha Mahmoud Barry, Dr
Role: PRINCIPAL_INVESTIGATOR
Santé Plus
Seydou Doumbia, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Bamako
Sylvain Faye, Prof
Role: PRINCIPAL_INVESTIGATOR
Cheikh Anta Diop University, Senegal
Abdullah Mbawah, Dr
Role: PRINCIPAL_INVESTIGATOR
University of Freetown
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henri Gautier Ouedragogo
Ouagadougou, , Burkina Faso
Alpha Mahmoud Barry
Conakry, , Guinea
Seydou Doumbia
Bamako, , Mali
Sylvain Faye
Dakar, , Senegal
Abdul Mbawah
Freetown, , Sierra Leone
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161-4. doi: 10.1016/j.vaccine.2015.04.036. Epub 2015 Apr 17.
Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 Feb;27(2):225-228. doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20.
Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021 Apr;6(4):e210-e221. doi: 10.1016/S2468-2667(21)00012-8. Epub 2021 Feb 6.
Samarasekera U. Feelings towards COVID-19 vaccination in Africa. Lancet Infect Dis. 2021 Mar;21(3):324. doi: 10.1016/S1473-3099(21)00082-7. No abstract available.
Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R's). BMC Public Health. 2019 Dec 11;19(1):1665. doi: 10.1186/s12889-019-7978-4.
Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, Schuster M, MacDonald NE, Wilson R; SAGE Working Group on Vaccine Hesitancy. Measuring vaccine hesitancy: The development of a survey tool. Vaccine. 2015 Aug 14;33(34):4165-75. doi: 10.1016/j.vaccine.2015.04.037. Epub 2015 Apr 18.
Di Meglio F, Lhomme E, Ouedraogo HG, Barry AM, Doumbia S, Faye SL, Mbawah AK, Sagna T, Tounkara M, Strauss R, Doumbia CO, Diouf S, Cisse K, May J, Puradiredja DI, Fusco D. Variations in COVID-19 vaccine hesitancy over time: a serial cross-sectional study in five West African countries. BMJ Open. 2024 Nov 7;14(11):e083766. doi: 10.1136/bmjopen-2023-083766.
Faye SLB, Krumkamp R, Doumbia S, Tounkara M, Strauss R, Ouedraogo HG, Sagna T, Barry AM, Mbawah AK, Doumbia CO, Diouf S, Cisse K, Harding M, Donven P, May J, Puradiredja DI, Fusco D; ACHES consortium. Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: a cross-sectional study. BMJ Open. 2022 Apr 13;12(4):e059138. doi: 10.1136/bmjopen-2021-059138.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-10550-BO-ff
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.